Skip to main content

Table 5 Calculated and targeted antibiotic therapy with suspected or proven IAI with multi-resistant agents

From: Antimicrobial Treatmdent of "Complicated" Intra-Abdominal Infections and The New IDSA Guidelines - A Commentary and an Alternative European Approach According to Clinical Definitions

Agent Antibiotic Level of evidence Strength of recommendation
MRSA Tigecycline# 2 A
  Linezolid+ 3 A
  Daptomycin+ 4 C
  Vancomycin+ 4 B
  Cotrimoxazole+ 4 C
VRE Tigecycline# 2 A
  Linezolid+ 3 A
ESBL-producing (E. coli, Klebsiella spp.) Imipenem 3 A
  Meropenem 3 A
  Doripenem 3 A
  Ertapenem# 3 A
  Tigecycline# 2 A
  Acylaminopenicillin/BLI 3 A
  Fosfomycin 4 B
Pseudomonas spp. Imipenem 4 A
  Meropenem 4 A
  Doripenem 4 A
  Acylaminopenicillin/BLI 4 A
  Cefepim 4 A
  Aminoglycoside 4 B
  Ciprofloxacin* 4 A
  Levofloxacin* 4 A
Acinetobacter spp. Colistin 2 A
  Tigecycline# 4 A
Carbapenemase-producing (i.e. KPC)species Tigecycline# 4 A
  Colistin 4 B
  1. (MRSA = Methicillin resistant S. aureus, VRE = Vancomycin-resistant Enterococcus spp., ESBL = extended spectrum beta-lactamase producing species, + = Combination with antibiotics covering gram negative and anaerobic species required, # = Combination with Pseudomonas-active antibiotics required if Pseudomonas is suspected; = no monotherapy, * = use antibiotic only if local susceptibility rates are ≥ 90%.